These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. Gebbia V; Gridelli C; Verusio C; Frontini L; Aitini E; Daniele B; Gamucci T; Mancuso G; Di Maio M; Gallo C; Perrone F; Morabito A Lung Cancer; 2009 Feb; 63(2):251-8. PubMed ID: 18632181 [TBL] [Abstract][Full Text] [Related]
32. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Belani CP; Schreeder MT; Steis RG; Guidice RA; Marsland TA; Butler EH; Ramalingam SS Cancer; 2008 Nov; 113(9):2512-7. PubMed ID: 18816622 [TBL] [Abstract][Full Text] [Related]
33. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer. Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622 [TBL] [Abstract][Full Text] [Related]
34. Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy. Kaynak A; Davis HW; Kogan AB; Lee JH; Narmoneva DA; Qi X Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626139 [TBL] [Abstract][Full Text] [Related]
35. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522 [TBL] [Abstract][Full Text] [Related]
36. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208 [TBL] [Abstract][Full Text] [Related]
37. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy. Larkins E; Scepura B; Blumenthal GM; Bloomquist E; Tang S; Biable M; Kluetz P; Keegan P; Pazdur R Oncologist; 2015 Nov; 20(11):1320-5. PubMed ID: 26446239 [TBL] [Abstract][Full Text] [Related]
38. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015 [TBL] [Abstract][Full Text] [Related]
39. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data. Reboul FL Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280 [TBL] [Abstract][Full Text] [Related]
40. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]